Cancer Gene Therapy
Dendreon Announces FDA's Cellular, Tissue and Gene Therapies Advisory Committee to Review Provenge for the Treatment of Asymptomatic, Metastatic, Androgen-Independent Prostate Cancer
Published in Gene Therapy Weekly, March 15th, 2007
Dendreon Corporation (NASDAQ:DNDN) announced that the U.S. Food and Drug Administration's Office of Cellular, Tissue and Gene Therapies Advisory Committee will review the Biologics License Application (BLA) for PROVENGE (sipuleucel-T), the Company's investigational active cellular immunotherapy (ACI) for the treatment of asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer on March 29, 2007. The Center for Biologics Evaluation and Research (CBER) has oversight of the Cellular, Tissue and Gene Therapy Advisory Committee.
Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2007-03-15)
More Articles from Gene Therapy Weekly
- Critical Limb Ischemia
Gene therapy shows promise as treatment for diseased limbs - Regenerative Medicine
Forsyth scientists make major discovery to advance regenerative medicine - Allergies
Reported to the American Academy of Allergy, Asthma and Immunology: Pittsburgh Physicians Find Genetic Clue to Children's Risk of Ear Infection Triggered by Common Cold - Antisense Technology
AVI BioPharma Presents Novel HIV Drug Candidate Results - Financing
Advanced BioHealing Raises $25.5 Million in Series C Financing - Financing
Safeguard Scientifics Leads $25.5 Million Series C Financing for Advanced BioHealing, Inc. - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
